CD8A and non-small cell lung carcinoma: Additionally, it has been reported that inhibiting this pathway using PI-3K inhibitors, such as LY294002, can induce apoptosis in NSCLC cells, enhance CD8 + T cell infiltration, reverse PD-L1-mediated immunosuppression, and increase chemotherapy sensitivity [60,61].